KU Cancer Center-invented drug targets transforming bladder cancer treatment

CicloMed LLC has expanded a clinical trial for an anti-cancer drug that potentially could transform the treatment of bladder cancer. Researchers at The University of Kansas Cancer Center and its Institute for Advancing Medical Innovation (IAMI) first discovered the treatment several years ago. Now, the drug is licensed to CicloMed, a Kansas City-based biotechnology company formed by IAMI and Kansas City venture capital firm Bio Novus Innovations LLC. Fosciclopirox is set to become the first KU Cancer…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news